MedCity News
OCTOBER 24, 2022
Cofertility is a new startup aiming to make egg freezing more accessible by tying it to egg donation. The startup offers women two programs: Keep and Split. With Keep, women can pay to freeze their eggs and store them all for their own later use. The Split program allows women to freeze their eggs for free when they give half to a family who can’t otherwise conceive.
Medgadget
OCTOBER 27, 2022
A team of scientists at Penn State has bioprinted breast tumor mimics with significant complexity, including a form of vascularization and the ability to precisely place cells in certain locations within the construct. The scientists used a technique called aspiration-assisted bioprinting to achieve this. With many anti-cancer therapies failing at the clinical trial stage and the ethical considerations of animal studies, there is a need for better in vitro cancer models that allow for advanced t
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 28, 2022
Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Considering the low chances of success, with only 10% of drug candidates making it into clinical development, pharma companies must prevent the increased erosion of profit margins.
PM360
OCTOBER 28, 2022
Over the past decade, macro trends in healthcare have pushed life sciences companies to pursue increasingly sophisticated key account management (KAM) strategies and capabilities to provide unique offerings and value. This capability requires an orchestrated, cross-functional go-to-market model designed to address the needs and engagement preferences of a defined segment of large, complex, and strategically important healthcare systems and groups.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
OCTOBER 28, 2022
CAR-T has become increasingly recognized as an exciting and potentially paradigm-shifting treatment in the past five years. In fact, more than 10,000 patients have undergone this new treatment for certain types of leukemia, lymphoma. and multiple myeloma.
Medgadget
OCTOBER 25, 2022
Scientists at Oregon State University have developed a new treatment for COVID-19. The technology is based on mRNA, which has also been put to good use in COVID-19 vaccines. However, in this instance, the delivered mRNA encodes for human angiotensin-converting enzyme 2 (hACE2), which is the binding site for SARS-CoV-2 on airway cells. The lipid nanoparticle-encapsulated mRNA therapeutic is delivered to cells in the body, and then the cells begin to produce and release a free-floating form of hAC
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
OCTOBER 28, 2022
Biotech firm Omega Therapeutics, Inc. revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. OTX-2002 targets c-Myc (MYC), a key oncogene and master transcription factor that regulates cell proliferation, differentiation and apoptosis and plays a major role in over half of all human cancers.
MedCity News
OCTOBER 24, 2022
In order to engage more Americans in primary care, we need to understand the main challenges that surround primary care in the U.S., according to Dr. Stephen Ezeji-Okoye, Crossover Health’s chief medical officer. Some of these include the increasing shortage of primary care physicians and the lack of incentivization to focus on whole-person health and preventive care.
Medgadget
OCTOBER 25, 2022
Researchers at Osaka University in Japan engineered a wearable electroencephalography (EEG) device that can measure brain activity, potentially letting clinicians monitor conditions such as depression or dementia. At present, assessing brain activity requires a trip to a facility with bulky and expensive equipment, making long-term monitoring difficult.
pharmaphorum
OCTOBER 25, 2022
Novartis has abandoned development of its drug to treat presbyopia, a common age-related loss of near distance vision, after it failed a phase 2b trial. The eyedrop formulation of UNR844 (lipoic acid/choline ester chloride) was acquired as part of the group’s buyout of privately-held ophthalmology biotech Encore Vision for $375 million upfront in 2017, and was designed to work by restoring the elasticity of the eye’s lens that declines with age.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
OCTOBER 25, 2022
AstraZeneca’s Imfinzi (durvalumab) and Imjudo (tremelimumab) combination therapy has been approved in the US for adult patients with unresectable hepatocellular carcinoma (HCC). Phase III trial results found that three years post-treatment, 31 percent of patients given the drug combination were still alive. The statistic for those just offered sorafenib was 20 percent.
MedCity News
OCTOBER 25, 2022
Through apps, pharmaceutical companies can actually influence patient adherence and mindset after that patient has been prescribed that company’s medication by their physician.
PharmaVoice
OCTOBER 25, 2022
The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.
PM360
OCTOBER 28, 2022
Shepherding a new drug to market is a long, expensive, and uncertain process. On average, it requires 10 to 12 years and $2.6 billion dollars to bring a new drug from discovery to regulatory approval and market launch. Approval success rates of drug candidates are between 10%–20% in the United States, the European Union, and Japan. During the last decade, the return on investment in drug development has seen diminishing returns.
European Pharmaceutical Review
OCTOBER 27, 2022
The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) has released new data on the US bioscience industry, indicating it was valued at $2.9 trillion dollars in 2021. The report also found that in 2021, the US industry employed 2.1 million people in over 127,000 businesses. The report , developed in partnership by TEConomy Partners and BIO, is the tenth in a biennial series that assesses the state of the US bioscience industry and its innovation s
MedCity News
OCTOBER 28, 2022
The innovation platform promises to match entrepreneurs with the resources they need to advance treatments for stroke care but also to help the device maker process all the new ideas it sees.
PharmaVoice
OCTOBER 26, 2022
The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.
Pharmaceutical Technology
OCTOBER 25, 2022
Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). There are options in the future to possibly apply the worldwide research and development (R&D), manufacturing and marketing expertise of Astellas in gene therapy to AAV gene therapy development programmes of Taysha for genetic ailments of the central nervous system (CNS).
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
OCTOBER 26, 2022
Some 70-80% of antibody drug conjugate (ADC) developers outsource their operations to contract development and manufacturing organisations (CDMOs) to yield cost savings opportunities, according to a recent market report. Manufacturing agreements emerged as the most popular type of partnership model for ADC developers, adopted by 18 percent of stakeholders, followed by product development agreements (16 percent) and research agreements (15 percent), the market research found. .
MedCity News
OCTOBER 26, 2022
Consumer-led healthcare will change patient care pathways, driving the industry to grow and collaborate in new ways, both with patients around their own health and with partners and innovators.
PM360
OCTOBER 27, 2022
Krystal Biotech, Inc. , a clinical-stage biopharmaceutical company focused on gene therapies for dermatological diseases, recently announced positive results from a Phase 3 clinical trial on its investigational compound Beremagene Geperpavec (B-VEC), a topical gene therapy designed to treat the debilitating skin condition dystrophic epidermolysis bullosa (DEB).
pharmaphorum
OCTOBER 26, 2022
Drugmakers Pfizer and Flynn Pharma have formally launched an appeal against a £70 million ($84 million) fine levied by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug. The two drugmakers were fined in July, after the CMA upheld a preliminary judgment that Pfizer and Flynn had abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to swell from around £2 million a year in 2012 to £50 million the following y
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
OCTOBER 27, 2022
Elements leading to a rational design of cyclodextrin-based formulations. Cyclodextrins are a frequently used excipient in the pharmaceutical industry, employed in multiple dosage forms and with multiple purposes simply because of their numerous positive properties, including being generally well tolerated and safe. In this short article, René Holm, Professor in pharmaceutical physical chemistry at the University of Southern Denmark, provides a few examples of how a rational formulation design f
MedCity News
OCTOBER 28, 2022
Hazel Health, a company that provides school-based telehealth, has closed a $51.5 million Series C1 funding round. The company also announced it has deployed its services in more than 3,000 schools across 14 states.
PM360
OCTOBER 28, 2022
Understanding the journeys of healthcare professionals and patients when prescribing and receiving treatments has never been more important. As the industry struggles to maintain the same levels of productivity in R&D as in previous years, a greater emphasis than ever is being placed on providing an accurate estimation of demand and prescription trends.
pharmaphorum
OCTOBER 25, 2022
AstraZeneca’s IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker’s efforts to expand its label keep running into difficulties. Earlier this year, the FDA rejected AZ’s application for Fasenra (benralizumab) as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) with a request for more data.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Copyright Clearance Center
OCTOBER 26, 2022
October 26, 20 22 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, has earned several 2022 Top Workplaces Culture Excellence Awards for Employee Appreciation, Employee Well-Being, Professional Development, and being Women-Led. Earlier this year, CCC won national recognition for Compensation & Benefits, Leadership, and Work-Life Flexibility.
MedCity News
OCTOBER 28, 2022
The investigation also found that companies denied exceptions requests on average four or more times out of ten, raising barriers to accessing birth control, according to a news release on Tuesday.
European Pharmaceutical Review
OCTOBER 28, 2022
A new report , Addressing Europe’s Medicine Exodus by Teva called on legislators to ensure a safer, more secure supply of essential medicines for EU patients, by cutting reliance on low-cost markets. Teva stated distant suppliers and supply chains, weakened by pressures such as inflation are at risk. Europe may not be able to guarantee a reliable supply of necessary drugs alongside rising demand.
Pharmaceutical Technology
OCTOBER 25, 2022
BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. Under the joint research project, a new research team will be set up at the BioMed X Institute in Heidelberg, Germany. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.
Expert insights. Personalized for you.
136 
Let's personalize your content